Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...

Patients in the open-label phase II trial had progressed on at least one gemcitabine-containing regimen and received ...

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Recent developments in health news highlight the CDC's anticipation of increased COVID-19 and RSV cases during the holidays, ...

Jazz Pharmaceuticals (JAZZ) stock and Zymeworks (ZYME) stock gain as FDA clears their cancer therapy Ziihera. Read more here.

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

The biotech’s liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks ...